Bavencio

05.04.2023 • News

Germany’s Merck Ends Bavencio Pact with Pfizer

Germany’s Merck will regain exclusive worldwide rights to develop, manufacture and commercialize the anti-programmed death ligand-1 (PD-L1) antibody Bavencio (avelumab) following the termination of its Alliance agreement with US drugs giant Pfizer, planned for the end of the second quarter.

Top-Feature

IMCD Deutschland GmbH

Fostering Innovation and Collaboration

Evonik Industries AG

Maximize the Potential of Spent Hydroprocessing Catalysts

Ecocool GmbH

Transport Logistic: Ecocool Presents Packaging Solutions for Pharmaceutical Transports

Innovation Pitch

Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.